• Aucun résultat trouvé

Brain molecular imaging in pharmacoresistant focal epilepsy: Current practice and perspectives

N/A
N/A
Protected

Academic year: 2021

Partager "Brain molecular imaging in pharmacoresistant focal epilepsy: Current practice and perspectives"

Copied!
35
0
0

Texte intégral

Loading

Références

Documents relatifs

To assess whether the hyperintensity of FCD lesions (i.e. the fact that they are characterized by higher signal intensity than the normal cortex) has a significant impact

Columns show the different steps of the procedure and the corresponding manual label: (A) initialization with the classifier (yellow contour), (B) intermediate result with the FDM

Noticeably, sub-continuous rhythmic spiking, classically described as pathognomonic of FCD type II, in particular in the presence of balloon cells (FCD IIb) [24, 25], was

We used high-density EEG to measure connectivity in large ‐ scale functional networks of patients with focal epilepsy (Temporal and Extratemporal Lobe Epilepsy, TLE and ETLE) and

Our findings have several original features: (1) the first report of patients with FCDs associated with DEPDC5 mutations who underwent epilepsy surgery, and demonstration of a

3. Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Heron SE, Smith KR, Bahlo M, et

Germline mutations in disheveled, Egl-10, and pleckstrin (DEP) domain-containing 5 (DEPDC5), have recently been described in a range of focal epilepsy syndromes including

Language and verbal memory functions, which are inextricably bound up with intrinsic networks based on temporal hubs, are normally lateralized in the left hemisphere in healthy